167. マルファン症候群 Marfan syndrome Clinical trials / Disease details


臨床試験数 : 21 薬物数 : 40 - (DrugBank : 11) / 標的遺伝子数 : 10 - 標的パスウェイ数 : 50

  
12 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT00782327
(ClinicalTrials.gov)
November 1, 200929/10/2008Randomized, Double-blind Study for the Evaluation of the Effect of Losartan Versus Placebo on Aortic Root Dilatation in Patients With Marfan Syndrome Under Treatment With Beta-blockersRandomized, Double-blind Study for the Evaluation of the Effect of Losartan Versus Placebo on Aortic Root Dilatation in Patients With Marfan Syndrome Under Treatment With Beta-blockersMarfan SyndromeDrug: Losartan;Drug: PlaceboUniversity Hospital, GhentAgentschap voor Innovatie door Wetenschap en TechnologieCompleted10 YearsN/AAll22Phase 3Belgium
2EUCTR2007-005862-10-BE
(EUCTR)
29/05/200907/01/2009Randomized, double-blind study for the evaluation of the effect of losartan versus placebo on aortic root dilatation in patients with Marfan syndrome under treatment with beta-blockers.Randomized, double-blind study for the evaluation of the effect of losartan versus placebo on aortic root dilatation in patients with Marfan syndrome under treatment with beta-blockers. Marfan syndrome
MedDRA version: 9.1;Level: LLT;Classification code 10026829;Term: Marfan's syndrome
Trade Name: Cozaar
Product Name: Losartan
INN or Proposed INN: Losartan potassium
Trade Name: Coozar
Product Name: Losartan
INN or Proposed INN: Losartan potassium
Trade Name: Coozar
Product Name: Losartan
INN or Proposed INN: Losartan potassium
University Hospital GhentNULLNot RecruitingFemale: yes
Male: yes
Belgium
3EUCTR2008-001462-81-IT
(EUCTR)
27/10/200817/03/2008Effects of Losartan versus Nebivolol versus the association of both on the progression of aortic root dilation in Marfan Syndrome (MFS) with FBN1 gene mutations - NDEffects of Losartan versus Nebivolol versus the association of both on the progression of aortic root dilation in Marfan Syndrome (MFS) with FBN1 gene mutations - ND Marfan Syndrome
MedDRA version: 9.1;Level: LLT;Classification code 10026829;Term: Marfan's syndrome
Trade Name: LORTAAN*28CPR RIV DIV 50MG
INN or Proposed INN: Losartan
Trade Name: LOBIVON*28CPR 5MG
INN or Proposed INN: Nebivolol
OSPEDALE POLICLINICO S. MATTEONULLNot RecruitingFemale: yes
Male: yes
Phase 3Italy
4NCT01145612
(ClinicalTrials.gov)
October 200815/6/2010Atenolol Versus Losartan in the Prevention of Progressive Dilation of the Aorta in Marfan SyndromeA Clinical Trial to Assess the Efficacy and Safety of Losartan Versus Atenolol in the Prevention of Progressive Dilation of the Aorta in Patients With Marfan Syndrome.Marfan SyndromeDrug: Losartan;Drug: AtenololForteza, Albert, M.D.Ministry of Health, SpainActive, not recruiting5 Years60 YearsBoth140Phase 3Spain
5NCT00763893
(ClinicalTrials.gov)
September 200830/9/2008Study of the Efficacy of Losartan on Aortic Dilatation in Patients With Marfan SyndromeMulticenter, Randomised, Double Blind Study of the Efficacy of Losartan on Aortic Dilatation in Patients With Marfan SyndromeMarfan SyndromeDrug: placebo;Drug: LosartanAssistance Publique - Hôpitaux de ParisNULLTerminated10 YearsN/ABoth303Phase 3France
6NCT00683124
(ClinicalTrials.gov)
July 200821/5/2008Nebivolol Versus Losartan Versus Nebivolol+Losartan Against Aortic Root Dilation in Genotyped Marfan PatientsEffects of Losartan vs. Nebivolol vs. the Association of Both on the Progression of Aortic Root Dilation in Marfan Syndrome (MFS) With FBN1 Gene Mutations.Marfan SyndromeDrug: Losartan and nebivolol;Drug: Losartan;Drug: NebivololIRCCS Policlinico S. MatteoMerck Sharp & Dohme Corp.;Menarini GroupRecruiting12 Months55 YearsBoth291Phase 3Italy
7EUCTR2007-001125-97-ES
(EUCTR)
20/05/200803/12/2007Eficacia y Seguridad de Losartán vs Atenolol en la prevención de la dilatación progresiva de la aorta en la población de pacientes con Síndrome de Marfan (Losartan vs atenolol efficacy and security in aortic dilatation prevention in Marfan syndrome)Eficacia y Seguridad de Losartán vs Atenolol en la prevención de la dilatación progresiva de la aorta en la población de pacientes con Síndrome de Marfan (Losartan vs atenolol efficacy and security in aortic dilatation prevention in Marfan syndrome) The aortic dilatation in Marfan syndrome with two different treatments: losartan vs atenolol
MedDRA version: 9.1;Level: LLT;Classification code 10026829;Term: Marfan's syndrome
Trade Name: cozaar 50
INN or Proposed INN: LOSARTAN POTASSIUM
Trade Name: blokium 50
INN or Proposed INN: ATENOLOL
Trade Name: COZAAR INICIO 12,5 mg comprimidos recubiertos con pelicula
INN or Proposed INN: LOSARTAN POTASSIUM
Trade Name: BLOKIUM 50 mg comprimidos
INN or Proposed INN: ATENOLOL
alberto fortezaNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
Spain
8NCT00593710
(ClinicalTrials.gov)
January 20083/1/2008Losartan Versus Atenolol for the Treatment of Marfan SyndromeA Randomized Double-blind Study Assessing the Effects of Losartan Versus Atenolol on Pulse Wave Velocity and the Biophysical Properties of the Aorta in Patients With Marfan SyndromeMarfan SyndromeDrug: Losartan;Drug: AtenololUniversity of British ColumbiaHeart and Stroke Foundation of CanadaCompleted12 Years25 YearsBoth17Phase 2Canada
9NCT00723801
(ClinicalTrials.gov)
October 200725/7/2008Effects of Losartan Versus Atenolol on Aortic and Cardiac Muscle Stiffness in Adults With Marfan SyndromeEffects of Losartan vs Atenolol on Aortic Stiffness and Diastolic Function in Adults With Marfan SyndromeMarfan SyndromeDrug: Atenolol;Drug: LosartanBrigham and Women's HospitalBoston Children’s HospitalCompleted25 YearsN/AAll40Phase 3United States
10NCT00651235
(ClinicalTrials.gov)
February 20073/3/2008A Randomized, Open-label, LOSARTAN Therapy on the Progression of Aortic Root Dilation in Patients With Marfan SyndromeA Randomized, Open-label, Active Control Trial to Evaluate the Effect of LOSARTAN Therapy on the Progression of Aortic Root Dilation in Patients With Marfan SyndromeMarfan SyndromeDrug: Losartan and Atenolol or Propranolol;Drug: Atenolol or PropranololNational Taiwan University HospitalNULLRecruiting1 YearN/ABoth44Phase 2Taiwan
11NCT00429364
(ClinicalTrials.gov)
January 200729/1/2007Comparison of Two Medications Aimed at Slowing Aortic Root Enlargement in Individuals With Marfan Syndrome--Pediatric Heart NetworkTrial of Beta Blocker Therapy (Atenolol) Versus Angiotensin II Receptor Blocker Therapy (Losartan) in Individuals With Marfan Syndrome (A Trial Conducted by the Pediatric Heart Network)Marfan SyndromeDrug: Losartan Potassium;Drug: AtenololNew England Research InstitutesNational Heart, Lung, and Blood Institute (NHLBI);FDA Office of Orphan Products Development;National Marfan FoundationCompleted6 Months25 YearsAll608Phase 3United States;Belgium;Canada
12EUCTR2006-003991-37-BE
(EUCTR)
13/12/200606/12/2006Trial of beta blocker therapy (atenolol) vs. angiotensin II receptor blocker therapy (losartan) in individuals with Marfan syndrome - Marfan TrialTrial of beta blocker therapy (atenolol) vs. angiotensin II receptor blocker therapy (losartan) in individuals with Marfan syndrome - Marfan Trial Marfan syndrome
MedDRA version: 8.1;Level: LLT;Classification code 10026829;Term: Marfan's syndrome
Product Name: losartan
INN or Proposed INN: Losartan potassium
Product Name: losartan
INN or Proposed INN: Losartan potassium
Product Name: losartan
INN or Proposed INN: Losartan potassium
Product Name: Atenolol
INN or Proposed INN: Atenolol
Product Name: Atenolol
INN or Proposed INN: Atenolol
Product Name: Atenolol
INN or Proposed INN: Atenolol
University Hospital GentNULLNot RecruitingFemale: yes
Male: yes
600Belgium